NHLBI Archives

Long QT syndrome – revealed

Mar. 12, 2018—Vanderbilt investigators have used sophisticated cell biological and structural techniques to “classify” mutations in potassium channels, studies that could lead to personalized treatment of heart rhythm disorders.

Mitochondrial mutations and disease

Feb. 22, 2018—New findings suggest that oxidative stress damages mitochondrial DNA, and they link this damage to a disease state.

Protecting transplanted lungs

Feb. 12, 2018—Acetaminophen may offer a simple treatment to prevent tissue injury following lung transplant, Vanderbilt researchers have discovered.

Muscular dystrophy clue

Feb. 9, 2018—Vanderbilt investigators have discovered a role for immune system T cells in slowing the decline in skeletal muscle function in patients with Duchenne muscular dystrophy.

Wear Red Day

Feb. 8, 2018—Members of Vanderbilt Heart and Vascular Institute (VHVI) gathered for a photo last week to recognize National Wear Red Day.

HDL and kidney injury after surgery

Jan. 17, 2018—Higher concentrations of high-density lipoproteins — HDL, the “good” cholesterol — may be protective against acute kidney injury after cardiac surgery, Vanderbilt researchers have discovered.

Obesity interventions: ideal dose?

Dec. 21, 2017—The optimal “dose” for behavioral interventions to treat childhood obesity are not clear, Vanderbilt researchers concluded after analyzing 133 clinical trial that occurred over the course of 17 years.

Radiation and pulmonary fibrosis

Nov. 15, 2017—To develop strategies for preventing radiation-induced lung fibrosis (scarring), Vanderbilt investigators are exploring the cell types and factors that contribute to the fibrotic response.

Salt, inflammation and hypertension

Nov. 13, 2017—Vanderbilt researchers have identified a pathway that links excess sodium, inflammation and hypertension.

Block estrogen to treat lung disease

Aug. 17, 2017—Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health.